Stem definition | Drug id | CAS RN |
---|---|---|
2872 | 68291-97-4 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.80 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 22 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 40.39 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
March 27, 2000 | FDA | EISAI INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Seizure | 603.64 | 41.25 | 168 | 1117 | 24298 | 2332502 |
Drug reaction with eosinophilia and systemic symptoms | 458.51 | 41.25 | 101 | 1184 | 5417 | 2351383 |
Stevens-Johnson syndrome | 214.09 | 41.25 | 52 | 1233 | 4207 | 2352593 |
Drug ineffective | 184.37 | 41.25 | 106 | 1179 | 101518 | 2255282 |
Epilepsy | 131.80 | 41.25 | 36 | 1249 | 4603 | 2352197 |
Cognitive disorder | 122.01 | 41.25 | 35 | 1250 | 5346 | 2351454 |
Toxic epidermal necrolysis | 120.79 | 41.25 | 31 | 1254 | 3113 | 2353687 |
Multiple-drug resistance | 120.32 | 41.25 | 20 | 1265 | 221 | 2356579 |
Drug eruption | 119.69 | 41.25 | 31 | 1254 | 3228 | 2353572 |
Therapeutic response unexpected | 109.81 | 41.25 | 30 | 1255 | 3829 | 2352971 |
Exposure during pregnancy | 103.38 | 41.25 | 46 | 1239 | 25173 | 2331627 |
Product substitution issue | 88.71 | 41.25 | 27 | 1258 | 5042 | 2351758 |
Rash | 88.47 | 41.25 | 55 | 1230 | 59503 | 2297297 |
Condition aggravated | 78.30 | 41.25 | 41 | 1244 | 31938 | 2324862 |
Psychotic disorder | 77.93 | 41.25 | 24 | 1261 | 4655 | 2352145 |
Somnolence | 77.84 | 41.25 | 37 | 1248 | 23448 | 2333352 |
Hyperammonaemic encephalopathy | 74.85 | 41.25 | 14 | 1271 | 315 | 2356485 |
Suicidal behaviour | 74.35 | 41.25 | 15 | 1270 | 506 | 2356294 |
Status epilepticus | 73.87 | 41.25 | 20 | 1265 | 2458 | 2354342 |
Hepatic function abnormal | 71.70 | 41.25 | 24 | 1261 | 6068 | 2350732 |
Generalised tonic-clonic seizure | 70.59 | 41.25 | 23 | 1262 | 5349 | 2351451 |
Drug hypersensitivity | 68.93 | 41.25 | 43 | 1242 | 46600 | 2310200 |
Depression | 68.63 | 41.25 | 36 | 1249 | 28096 | 2328704 |
Pyrexia | 68.22 | 41.25 | 45 | 1240 | 53663 | 2303137 |
Vomiting | 67.63 | 41.25 | 50 | 1235 | 71552 | 2285248 |
Intentional overdose | 67.47 | 41.25 | 27 | 1258 | 11294 | 2345506 |
Oculomucocutaneous syndrome | 67.41 | 41.25 | 11 | 1274 | 107 | 2356693 |
Diplopia | 67.24 | 41.25 | 20 | 1265 | 3445 | 2353355 |
Coma | 66.01 | 41.25 | 25 | 1260 | 9031 | 2347769 |
Irritability | 62.68 | 41.25 | 22 | 1263 | 6405 | 2350395 |
Lichen planus | 58.39 | 41.25 | 12 | 1273 | 444 | 2356356 |
Drug interaction | 56.34 | 41.25 | 32 | 1253 | 29131 | 2327669 |
Dizziness | 50.91 | 41.25 | 39 | 1246 | 58626 | 2298174 |
Ureterolithiasis | 50.62 | 41.25 | 10 | 1275 | 302 | 2356498 |
Abortion spontaneous | 50.08 | 41.25 | 23 | 1262 | 13422 | 2343378 |
Calculus urinary | 48.25 | 41.25 | 9 | 1276 | 199 | 2356601 |
Depressed mood | 47.65 | 41.25 | 17 | 1268 | 5181 | 2351619 |
Lymphocyte stimulation test positive | 46.71 | 41.25 | 9 | 1276 | 238 | 2356562 |
Ataxia | 46.66 | 41.25 | 14 | 1271 | 2478 | 2354322 |
Weight decreased | 46.50 | 41.25 | 28 | 1257 | 28343 | 2328457 |
Agranulocytosis | 46.08 | 41.25 | 15 | 1270 | 3467 | 2353333 |
Decreased appetite | 46.03 | 41.25 | 28 | 1257 | 28863 | 2327937 |
Nephrolithiasis | 46.00 | 41.25 | 16 | 1269 | 4527 | 2352273 |
Brown tumour | 45.11 | 41.25 | 6 | 1279 | 10 | 2356790 |
Erythema multiforme | 44.12 | 41.25 | 13 | 1272 | 2162 | 2354638 |
Ovarian granulosa-theca cell tumour | 43.20 | 41.25 | 6 | 1279 | 16 | 2356784 |
Migraine | 42.10 | 41.25 | 19 | 1266 | 10634 | 2346166 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Seizure | 312.38 | 45.86 | 105 | 964 | 20336 | 1725376 |
Drug reaction with eosinophilia and systemic symptoms | 245.98 | 45.86 | 64 | 1005 | 5006 | 1740706 |
Stevens-Johnson syndrome | 215.20 | 45.86 | 53 | 1016 | 3304 | 1742408 |
Status epilepticus | 186.62 | 45.86 | 43 | 1026 | 2003 | 1743709 |
Drug ineffective | 118.70 | 45.86 | 76 | 993 | 63725 | 1681987 |
Aggression | 116.16 | 45.86 | 40 | 1029 | 8075 | 1737637 |
Toxic epidermal necrolysis | 110.07 | 45.86 | 29 | 1040 | 2342 | 1743370 |
Nephrolithiasis | 108.12 | 45.86 | 32 | 1037 | 3960 | 1741752 |
Condition aggravated | 97.24 | 45.86 | 46 | 1023 | 21104 | 1724608 |
Calculus urinary | 84.58 | 45.86 | 16 | 1053 | 275 | 1745437 |
Drug eruption | 81.54 | 45.86 | 24 | 1045 | 2902 | 1742810 |
Drug interaction | 79.51 | 45.86 | 44 | 1025 | 27914 | 1717798 |
Pyrexia | 72.99 | 45.86 | 50 | 1019 | 46350 | 1699362 |
Somnolence | 72.51 | 45.86 | 35 | 1034 | 16704 | 1729008 |
Rash | 71.20 | 45.86 | 46 | 1023 | 38647 | 1707065 |
Epilepsy | 70.32 | 45.86 | 23 | 1046 | 3936 | 1741776 |
Neonatal pneumonia | 67.47 | 45.86 | 10 | 1059 | 32 | 1745680 |
Foetal exposure during pregnancy | 63.26 | 45.86 | 24 | 1045 | 6335 | 1739377 |
Neonatal hypotension | 62.96 | 45.86 | 10 | 1059 | 56 | 1745656 |
Product substitution issue | 62.04 | 45.86 | 20 | 1049 | 3266 | 1742446 |
Hepatic function abnormal | 60.78 | 45.86 | 24 | 1045 | 7050 | 1738662 |
Oculomucocutaneous syndrome | 60.67 | 45.86 | 10 | 1059 | 73 | 1745639 |
Agranulocytosis | 56.39 | 45.86 | 19 | 1050 | 3557 | 1742155 |
Liver disorder | 51.48 | 45.86 | 20 | 1049 | 5616 | 1740096 |
Aspartate aminotransferase increased | 51.09 | 45.86 | 24 | 1045 | 10732 | 1734980 |
Neuroleptic malignant syndrome | 50.71 | 45.86 | 17 | 1052 | 3131 | 1742581 |
Respiratory disorder neonatal | 48.42 | 45.86 | 10 | 1059 | 273 | 1745439 |
Small for dates baby | 46.06 | 45.86 | 11 | 1058 | 590 | 1745122 |
Source | Code | Description |
---|---|---|
ATC | N03AX15 | NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics |
FDA EPC | N0000175753 | Anti-epileptic Agent |
FDA PE | N0000008486 | Decreased Central Nervous System Disorganized Electrical Activity |
FDA CS | M0020790 | Sulfonamides |
FDA MoA | N0000000235 | Carbonic Anhydrase Inhibitors |
FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
CHEBI has role | CHEBI:35623 | anticonvulsant |
CHEBI has role | CHEBI:35470 | central nervous system drug |
CHEBI has role | CHEBI:50267 | protective agent |
MeSH PA | D000927 | Anticonvulsants |
MeSH PA | D002121 | Calcium Channel Blockers |
MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Partial Epilepsy Treatment Adjunct | indication | ||
Suicidal thoughts | contraindication | 6471006 | |
Agranulocytosis | contraindication | 17182001 | DOID:12987 |
Mood swings | contraindication | 18963009 | |
Depressive disorder | contraindication | 35489007 | |
Metabolic acidosis | contraindication | 59455009 | |
Diarrhea | contraindication | 62315008 | |
Psychotic disorder | contraindication | 69322001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Kidney stone | contraindication | 95570007 | |
Diminished sweating | contraindication | 111980002 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Aplastic anemia | contraindication | 306058006 | DOID:12449 |
Severe chronic obstructive pulmonary disease | contraindication | 313299006 | |
Fever | contraindication | 386661006 | |
Surgical procedure | contraindication | 387713003 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.47 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium channel protein type 1 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 7.70 | CHEMBL | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 5.28 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 6.93 | CHEMBL | |||||
Carbonic anhydrase V | Enzyme | Ki | 7.69 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 5.07 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 5.22 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.51 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 6.37 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 7.05 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 8.30 | WOMBAT-PK | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 7.25 | WOMBAT-PK | |||||
Voltage-dependent T-type calcium channel subunit alpha-1G | Ion channel | WOMBAT-PK | |||||||
Carbonic anhydrase 2 | Enzyme | Ki | 6.99 | WOMBAT-PK | |||||
Carbonic anhydrase 12 | Enzyme | INHIBITOR | Ki | 4.96 | IUPHAR | ||||
Carbonic anhydrase | Unclassified | Ki | 6.19 | CHEMBL | |||||
Delta carbonic anhydrase | Unclassified | Ki | 6.39 | CHEMBL | |||||
Carbonic anhydrase 2 | Unclassified | Ki | 6.01 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 6.97 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 6.66 | CHEMBL | |||||
Carbonic anhydrase 15 | Enzyme | Ki | 6.20 | CHEMBL | |||||
Alpha carbonic anhydrase | Unclassified | Ki | 6.59 | CHEMBL | |||||
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase | Enzyme | Ki | 6.68 | CHEMBL | |||||
Carbonic anhydrase 3 | Enzyme | Ki | 5.07 | CHEMBL | |||||
Astrosclerin-3 | Unclassified | Ki | 6.78 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.54 | CHEMBL | |||||
Amine oxidase [flavin-containing] | Unclassified | Ki | 4.51 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 7.46 | CHEMBL | |||||
Beta-carbonic anhydrase 1 | Enzyme | Ki | 4.54 | CHEMBL | |||||
Carbonic anhydrase 2 | Enzyme | Ki | 6.06 | CHEMBL | |||||
Carbonic anhydrase | Unclassified | Ki | 6.58 | CHEMBL | |||||
Carbonic anhydrase | Enzyme | Ki | 6.94 | CHEMBL |
ID | Source |
---|---|
D000078305 | MESH_DESCRIPTOR_UI |
4021224 | VUID |
N0000148668 | NUI |
C0078844 | UMLSCUI |
D00538 | KEGG_DRUG |
459384H98V | UNII |
5575 | INN_ID |
398762003 | SNOMEDCT_US |
4021224 | VANDF |
73622 | MMSL |
008137 | NDDF |
d04527 | MMSL |
8781 | MMSL |
39998 | RXNORM |
125693002 | SNOMEDCT_US |
5734 | PUBCHEM_CID |
CHEBI:10127 | CHEBI |
CHEMBL750 | ChEMBL_ID |
DB00909 | DRUGBANK_ID |
ZON | PDB_CHEM_ID |
7047 | IUPHAR_LIGAND_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0193 | CAPSULE | 25 mg | ORAL | ANDA | 14 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0199 | CAPSULE | 50 mg | ORAL | ANDA | 14 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0200 | CAPSULE | 100 mg | ORAL | ANDA | 14 sections |
zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8266 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-539 | CAPSULE | 100 mg | ORAL | ANDA | 15 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-724 | CAPSULE | 25 mg | ORAL | ANDA | 13 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-155 | CAPSULE | 100 mg | ORAL | ANDA | 14 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-654 | CAPSULE | 50 mg | ORAL | ANDA | 14 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-228 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-843 | CAPSULE | 100 mg | ORAL | ANDA | 12 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35356-143 | CAPSULE | 100 mg | ORAL | ANDA | 14 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-932 | CAPSULE | 25 mg | ORAL | ANDA | 13 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-816 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-137 | CAPSULE | 25 mg | ORAL | ANDA | 13 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-138 | CAPSULE | 50 mg | ORAL | ANDA | 13 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-139 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53217-301 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5789 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6221 | CAPSULE | 50 mg | ORAL | ANDA | 13 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-945 | CAPSULE | 25 mg | ORAL | ANDA | 12 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-946 | CAPSULE | 50 mg | ORAL | ANDA | 12 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-990 | CAPSULE | 100 mg | ORAL | ANDA | 12 sections |
Zonegran | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59212-680 | CAPSULE | 100 mg | ORAL | NDA | 14 sections |
Zonegran | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59212-681 | CAPSULE | 25 mg | ORAL | NDA | 14 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-230 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61919-275 | CAPSULE | 50 mg | ORAL | ANDA | 11 sections |
Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61919-591 | CAPSULE | 50 mg | ORAL | ANDA | 14 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61919-749 | CAPSULE | 50 mg | ORAL | ANDA | 13 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61919-775 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61919-917 | CAPSULE | 100 mg | ORAL | ANDA | 12 sections |